Background
Methods
Study design
Model structure
Model parameters
Input parameters | Mean | Standard error | Distribution | Ref. |
---|---|---|---|---|
Transition probability parameters | ||||
Genotype 1 | ||||
chronic HCV to compensated cirrhosis year 1-10 | 0.0057 | 0.0057 | Beta | [24] |
chronic HCV to compensated cirrhosis year 11-20 | 0.0143 | 0.0141 | Beta | [24] |
chronic HCV to compensated cirrhosis year 21-30 | 0.0207 | 0.0203 | Beta | [24] |
chronic HCV to HCC year 1-10 | 0.0007 | 0.0007 | Beta | [24] |
chronic HCV to HCC year 11-20 | 0.0032 | 0.0032 | Beta | [24] |
chronic HCV to HCC year 21-30 | 0.0063 | 0.0062 | Beta | [24] |
chronic HCV to death | 0.0070 | 0.0070 | Beta | [25] |
compensated cirrhosis to decompensated cirrhosis year1-3 | 0.0417 | 0.0400 | Beta | [26] |
compensated cirrhosis to decompensated cirrhosis year 4-5 | 0.0945 | 0.0855 | Beta | [26] |
compensated cirrhosis to decompensated cirrhosis year 6-10 | 0.0662 | 0.0618 | Beta | [26] |
compensated cirrhosis to HCC year 1-3 | 0.0135 | 0.0133 | Beta | [26] |
compensated cirrhosis to HCC year 4-5 | 0.0356 | 0.0344 | Beta | [26] |
compensated cirrhosis to HCC year 6-10 | 0.0297 | 0.0288 | Beta | [26] |
compensated cirrhosis to death year 1-3 | 0.0135 | 0.0133 | Beta | [26] |
compensated cirrhosis to death year 4-5 | 0.0461 | 0.0439 | Beta | [26] |
compensated cirrhosis to death year 6-10 | 0.0461 | 0.0439 | Beta | [26] |
decompensated cirrhosis to HCC | 0.0681 | 0.0635 | Beta | [27] |
decompensated cirrhosis to death year 1 | 0.2600 | 0.1924 | Beta | [24] |
decompensated cirrhosis to death year 2 | 0.3900 | 0.2379 | Beta | [24] |
decompensated cirrhosis to death year 3-5 | 0.2394 | 0.1821 | Beta | [24] |
HCC to death year 1 | 0.8482 | 0.0011 | Beta | [28] |
HCC to death year 2 | 0.9201 | 0.0009 | Beta | [28] |
Genotype 6 | ||||
chronic HCV to compensated cirrhosis year 1-10 | 0.0057 | 0.0057 | Beta | [24] |
chronic HCV to compensated cirrhosis year 11-20 | 0.0143 | 0.0141 | Beta | [24] |
chronic HCV to compensated cirrhosis year 21-30 | 0.0207 | 0.0203 | Beta | [24] |
chronic HCV to HCC year 1-10 | 0.0007 | 0.0007 | Beta | [24] |
chronic HCV to HCC year 11-20 | 0.0032 | 0.0032 | Beta | [24] |
chronic HCV to HCC year 21-30 | 0.0063 | 0.0062 | Beta | [24] |
chronic HCV to death | 0.0070 | 0.0070 | Beta | [25] |
compensated cirrhosis to decompensated cirrhosis year 1-3 | 0.0417 | 0.0400 | Beta | [26] |
compensated cirrhosis to decompensated cirrhosis year 4-5 | 0.0945 | 0.0855 | Beta | [26] |
compensated cirrhosis to decompensated cirrhosis year 6-10 | 0.0662 | 0.0618 | Beta | [26] |
compensated cirrhosis to HCC year 1-3 | 0.0135 | 0.0133 | Beta | [26] |
compensated cirrhosis to HCC year 4-5 | 0.0356 | 0.0344 | Beta | [26] |
compensated cirrhosis to HCC year 6-10 | 0.0297 | 0.0288 | Beta | [26] |
compensated cirrhosis to death year 1-3 | 0.0135 | 0.0133 | Beta | [26] |
compensated cirrhosis to death year 4-5 | 0.0461 | 0.0439 | Beta | [26] |
compensated cirrhosis to death year 6-10 | 0.0461 | 0.0439 | Beta | [26] |
decompensated cirrhosis to HCC | 0.0681 | 0.0635 | Beta | [27] |
decompensated cirrhosis to death year 1 | 0.2600 | 0.1924 | Beta | [24] |
decompensated cirrhosis to death year 2 | 0.3900 | 0.2379 | Beta | [24] |
decompensated cirrhosis to death year 3-5 | 0.2394 | 0.1821 | Beta | [24] |
HCC to death year 1 | 0.8482 | 0.0011 | Beta | [28] |
HCC to death year 2 | 0.9201 | 0.0009 | Beta | [28] |
Virological responses | ||||
Genotype 1 | ||||
Pegylated interferon alpha 2b and Ribavirin | ||||
Probability of SVR | 0.2720 | 0.0057 | Beta | |
Probability of RVR | 0.1302 | 0.0033 | Beta | |
Probability to change from RVR to SVR | 0.8620 | 0.1190 | Beta | [29] |
Probability of NR | 0.2449 | 0.0055 | Beta | |
Pegylated interferon alpha 2a and Ribavirin | ||||
RR of SVR (peg 2a vs peg 2b) | 1.1950 | 0.0492 | Log normal | calculated |
RR of RVR (peg 2a vs peg 2b) | 1.1300 | 0.0353 | Log normal | calculated |
RR of NR (peg 2a vs peg 2b) | 0.6960 | 0.1134 | Log normal | calculated |
Genotype 6 | ||||
RR of SVR (gen 6 vs gen 1) | 1.2200 | Log normal | [32] | |
RR of RVR (gen 6 vs gen 1) | 1.6800 | Log normal | [32] | |
Health utility | ||||
Chronic hepatitis C infection | 0.7284 | 0.0011 | Beta | [13] |
Compensated cirrhosis | 0.7023 | 0.0020 | Beta | [13] |
Decompensated cirrhosis | 0.5774 | 0.0020 | Beta | [13] |
Hepatocellular carcinoma | 0.5778 | 0.0023 | Beta | [13] |
SVR (Healthy) | 0.7955 | 0.0018 | Beta | [13] |
Cost parameters | Mean | Standard error | Distribution | Ref. |
---|---|---|---|---|
Medication, laboratory and diagnostic tests costs | ||||
Pegylated interferon alfa-2a + Ribavirin (per week) | 3,150 | 630 | Gamma | [35] |
Pegylated interferon alfa-2b + Ribavirin (per week) | 3,150 | 630 | Gamma | [35] |
Investigation and monitoring | 16,277 | 3,255 | Gamma | [34] |
Direct medical cost for complication treatment | ||||
Costs of chronic HCV infection (per year) | 65,640 | 19,723 | Gamma | [33] |
Costs of compensated cirrhosis (per year) | 73,532 | 18,605 | Gamma | [33] |
Costs of decompensated cirrhosis (per year) | 138,141 | 18,996 | Gamma | [33] |
Costs of hepatocellular carcinoma (per year) | 168,899 | 11,601 | Gamma | [33] |
Direct non-medical cost for complication treatment | ||||
Costs of chronic HCV infection (per year) | 4,303 | 430.3 | Gamma | |
Costs of compensated cirrhosis (per year) | 4,216 | 421.6 | Gamma | |
Costs of decompensated cirrhosis (per year) | 5,823 | 582.3 | Gamma | |
Costs of hepatocellular carcinoma (per year) | 9,516 | 951.6 | Gamma |
Sensitivity analysis
Results
Alternative treatment | Genotype 1 | Genotype 6 | ||||
---|---|---|---|---|---|---|
Total costs (Baht) | QALYs (Year) | ICER (compare to palliative care) | Total costs (Baht) | QALYs (Year) | ICER (compare to palliative care) | |
Palliative care | 1,169,121 | 11.63 | - | 1,150,417 | 11.67 | - |
Peg 2a + RBV | 747,718 | 13.44 | Dominant | 558,868 | 14.07 | Dominant |
Peg 2b + RBV | 819,921 | 13.14 | Dominant | 655,697 | 13.69 | Dominant |